{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:02:13Z","timestamp":1783825333484,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T00:00:00Z","timestamp":1594512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T00:00:00Z","timestamp":1594512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ek0410025"],"award-info":[{"award-number":["JP16ek0410025"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10147-020-01732-8","type":"journal-article","created":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T07:02:48Z","timestamp":1594537368000},"page":"1861-1869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism"],"prefix":"10.1007","volume":"25","author":[{"given":"Ryo","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Kimishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Shiohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-5717","authenticated-orcid":false,"given":"Manabu","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,12]]},"reference":[{"issue":"11","key":"1732_CR1","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887\u20133895","journal-title":"EMBO J"},{"key":"1732_CR2","doi-asserted-by":"publisher","unstructured":"Scapin G, Yang X, Prosise WW et al (2015) Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol 22 (12):953\u2013958. https:\/\/doi.org\/10.1038\/nsmb.3129","DOI":"10.1038\/nsmb.3129"},{"key":"1732_CR3","doi-asserted-by":"publisher","unstructured":"Carbone DP, Reck M, Paz-Ares L et al (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 376 (25):2415\u20132426. https:\/\/doi.org\/10.1056\/NEJMoa1613493","DOI":"10.1056\/NEJMoa1613493"},{"key":"1732_CR4","doi-asserted-by":"publisher","unstructured":"Bekoz H, Karadurmus N, Paydas S et al (2017) Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Oncol 28 (10):2496\u20132502. https:\/\/doi.org\/10.1093\/annonc\/mdx341","DOI":"10.1093\/annonc\/mdx341"},{"issue":"7","key":"1732_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027\u20131034","journal-title":"J Exp Med"},{"key":"1732_CR6","doi-asserted-by":"publisher","unstructured":"Latchman Y, Wood CR, Chernova T et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2 (3):261\u2013268. https:\/\/doi.org\/10.1038\/85330","DOI":"10.1038\/85330"},{"key":"1732_CR7","doi-asserted-by":"publisher","unstructured":"Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99 (19):12293\u201312297. https:\/\/doi.org\/10.1073\/pnas.192461099","DOI":"10.1073\/pnas.192461099"},{"key":"1732_CR8","doi-asserted-by":"publisher","unstructured":"Osa A, Uenami T, Koyama S et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3 (19). https:\/\/doi.org\/10.1172\/jci.insight.59125","DOI":"10.1172\/jci.insight.59125"},{"key":"1732_CR9","doi-asserted-by":"publisher","unstructured":"Das R, Verma R, Sznol M et al (2015) Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194 (3):950\u2013959. https:\/\/doi.org\/10.4049\/jimmunol.1401686","DOI":"10.4049\/jimmunol.1401686"},{"issue":"5","key":"1732_CR10","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.4049\/jimmunol.176.5.2808","volume":"176","author":"G Raimondi","year":"2006","unstructured":"Raimondi G, Shufesky WJ, Tokita D et al (2006) Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol 176(5):2808\u20132816","journal-title":"J Immunol"},{"key":"1732_CR11","doi-asserted-by":"publisher","unstructured":"Pentcheva-Hoang T, Chen L, Pardoll DM et al (2007) Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A 104 (45):17765\u201317770. https:\/\/doi.org\/10.1073\/pnas.0708767104","DOI":"10.1073\/pnas.0708767104"},{"key":"1732_CR12","doi-asserted-by":"publisher","unstructured":"Saito H, Kuroda H, Matsunaga T et al (2013) Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol 107 (5):517\u2013522. https:\/\/doi.org\/10.1002\/jso.23281","DOI":"10.1002\/jso.23281"},{"key":"1732_CR13","doi-asserted-by":"publisher","unstructured":"MacFarlane AWt, Jillab M, Plimack ER et al (2014) PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res 2 (4):320\u2013331. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0133","DOI":"10.1158\/2326-6066.CIR-13-0133"},{"key":"1732_CR14","doi-asserted-by":"publisher","unstructured":"Kamphorst AO, Pillai RN, Yang S et al (2017) Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A 114 (19):4993\u20134998. https:\/\/doi.org\/10.1073\/pnas.1705327114","DOI":"10.1073\/pnas.1705327114"},{"key":"1732_CR15","doi-asserted-by":"publisher","unstructured":"Zelba H, Bochem J, Pawelec G et al (2018) Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer Immunol Immunother 67 (12):1845\u20131851. https:\/\/doi.org\/10.1007\/s00262-018-2244-7","DOI":"10.1007\/s00262-018-2244-7"},{"key":"1732_CR16","doi-asserted-by":"publisher","unstructured":"Barber DL, Wherry EJ, Masopust D et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (7077):682\u2013687. https:\/\/doi.org\/10.1038\/nature04444","DOI":"10.1038\/nature04444"},{"issue":"2","key":"1732_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.4049\/jimmunol.170.2.711","volume":"170","author":"F Bennett","year":"2003","unstructured":"Bennett F, Luxenberg D, Ling V et al (2003) Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 170(2):711\u2013718","journal-title":"J Immunol"},{"issue":"2","key":"1732_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE et al (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173(2):945\u2013954","journal-title":"J Immunol"},{"key":"1732_CR19","doi-asserted-by":"publisher","unstructured":"Nebenfuhr A, Ritzenthaler C, Robinson DG (2002) Brefeldin A: deciphering an enigmatic inhibitor of secretion. Plant Physiol 130 (3):1102\u20131108. https:\/\/doi.org\/10.1104\/pp.011569","DOI":"10.1104\/pp.011569"},{"key":"1732_CR20","doi-asserted-by":"publisher","unstructured":"Furui Y, Satake M, Hoshi Y et al (2013) Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Transfusion 53 (10):2190\u20132197. https:\/\/doi.org\/10.1111\/trf.12390","DOI":"10.1111\/trf.12390"},{"key":"1732_CR21","doi-asserted-by":"publisher","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2019) Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2187","DOI":"10.1001\/jamaoncol.2019.2187"},{"key":"1732_CR22","doi-asserted-by":"publisher","unstructured":"Tsukumo SI, Yasutomo K (2018) Regulation of CD8(+) T Cells and antitumor immunity by notch signaling. front Immunol 9:101. https:\/\/doi.org\/10.3389\/fimmu.2018.00101","DOI":"10.3389\/fimmu.2018.00101"},{"key":"1732_CR23","doi-asserted-by":"publisher","unstructured":"Hiroyasu S, Ozawa T, Kobayashi H et al (2013) Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway. Am J Pathol 182 (3):828\u2013840. https:\/\/doi.org\/10.1016\/j.ajpath.2012.11.029","DOI":"10.1016\/j.ajpath.2012.11.029"},{"key":"1732_CR24","doi-asserted-by":"publisher","unstructured":"Jin M, Hwang SM, Davies AJ et al (2012) Autoantibodies in primary Sjogren's syndrome patients induce internalization of muscarinic type 3 receptors. Biochim Biophys Acta 1822 (2):161\u2013167. https:\/\/doi.org\/10.1016\/j.bbadis.2011.11.012","DOI":"10.1016\/j.bbadis.2011.11.012"},{"key":"1732_CR25","doi-asserted-by":"publisher","unstructured":"Perera RM, Zoncu R, Johns TG et al (2007) Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia 9 (12):1099\u20131110. https:\/\/doi.org\/10.1593\/neo.07721","DOI":"10.1593\/neo.07721"},{"key":"1732_CR26","doi-asserted-by":"publisher","unstructured":"Sinclair E, Black D, Epling CL et al (2004) CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals. Viral Immunol 17 (3):445\u2013454. https:\/\/doi.org\/10.1089\/vim.2004.17.445","DOI":"10.1089\/vim.2004.17.445"},{"key":"1732_CR27","doi-asserted-by":"publisher","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (26):2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","DOI":"10.1056\/NEJMoa1200690"},{"key":"1732_CR28","doi-asserted-by":"publisher","unstructured":"Bellon T, Lerma V, Gonzalez-Valle O et al (2016) Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Br J Dermatol 174 (3):621\u2013624. https:\/\/doi.org\/10.1111\/bjd.14201","DOI":"10.1111\/bjd.14201"},{"key":"1732_CR29","doi-asserted-by":"publisher","unstructured":"Sinha R, Lecamwasam K, Purshouse K et al (2014) Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. Br J Dermatol 170 (4):997\u2013999. https:\/\/doi.org\/10.1111\/bjd.12796","DOI":"10.1111\/bjd.12796"},{"key":"1732_CR30","doi-asserted-by":"publisher","unstructured":"Wang C, Thudium KB, Han M et al (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2 (9):846\u2013856. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0040","DOI":"10.1158\/2326-6066.CIR-14-0040"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01732-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01732-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01732-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T23:25:11Z","timestamp":1626045911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01732-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,12]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01732-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,12]]},"assertion":[{"value":"20 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The Department of Dermatology, Kyorin University Faculty of Medicine (chaired by M.O.) receives financial support for academic activities not related to this study from ONO PHARMACEUTICAL CO.,LTD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}